This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaushal, V. Articles by Kohli, M. Search for Related Content PubMed PubMed Citation Articles by Kaushal, V. Articles by Kohli, M.

Stage-Specific Characterization of the Vascular Endothelial Growth Factor Axis in Prostate Cancer: Expression of Lymphangiogenic Markers Is Associated with Advanced-Stage Disease

Departments of ¹ Internal Medicine, ² Pathology, ³ Geriatrics, and ⁴ Biostatistics, University of Arkansas for Medical Sciences and Departments of ⁵ Urology and ⁶ Hematology/Oncology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas

Requests for reprints: Varsha Kaushal, Department of Internal Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences, 4301 West Markham, Slot 508, Little Rock AR 72205. Phone: 501-257-4813; Fax: 501-257-5867; E-mail: Kaushalvarsha{at}uams.edu.

Purpose: The vascular endothelial growth factor (VEGF) family plays a critical role in tumor angiogenesis and lymphangiogenesis. We characterized, at the mRNA and protein levels, the expression of VEGF-A and VEGF-D and their cognate receptors, VEGFR-1, VEGFR-2, and VEGFR-3 in early- and advanced-stage prostate cancer specimens.

Experimental Design: The levels of VEGF-A and VEGF-D mRNA in early- and advanced-stage specimens were compared using an angiogenic gene array and were confirmed by quantitative real-time PCR. Receptor protein levels and activation status were determined by immunoblotting. Spatial expression of the proteins was evaluated using immunohistochemistry with fresh and archival tissues from benign prostatic hypertrophy specimens, early-stage prostate specimens, and advanced-stage metastatic specimens. Circulating plasma levels of these growth factors were measured using ELISAs.

Results: We observed that expression patterns of VEGF isotypes corresponded to the prostate cancer stage: high expression of angiogenic growth factor VEGF-A was observed in early-stage prostate specimens, whereas high expression of lymphangiogenic growth factor VEGF-D was associated with advanced-stage metastatic disease. All VEGF receptors were present at variable levels in all specimens, but their activation states varied in a stage-specific manner. VEGFR-1 and, to a limited extent, VEGFR-2 were activated in early-stage specimens, whereas VEGFR-2 and VEGFR-3 were activated in advanced-stage specimens.

Conclusions: Our results suggest that lymphangiogenic markers, such as VEGF-D and VEGFR-2 and VEGFR-3, may be better than angiogenic markers as targets of therapeutic intervention in advanced-stage prostate disease.

Key Words: lymphangiogenesis • VEGF-D • VEGF-A • VEGF receptors

This article has been cited by other articles:

				R. S. Arnold, J. He, A. Remo, D. Ritsick, Q. Yin-Goen, J. D. Lambeth, M. W. Datta, A. N. Young, and J. A. Petros Nox1 Expression Determines Cellular Reactive Oxygen and Modulates c-fos-Induced Growth Factor, Interleukin-8, and Cav-1 Am. J. Pathol., December 1, 2007; 171(6): 2021 - 2032. [Abstract] [Full Text] [PDF]

				Y. Zeng, K. Opeskin, J. Goad, and E. D. Williams Tumor-Induced Activation of Lymphatic Endothelial Cells via Vascular Endothelial Growth Factor Receptor-2 Is Critical for Prostate Cancer Lymphatic Metastasis Cancer Res., October 1, 2006; 66(19): 9566 - 9575. [Abstract] [Full Text] [PDF]

				H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res., October 1, 2006; 12(19): 5841 - 5849. [Abstract] [Full Text] [PDF]

				S. Y. Wong, H. Haack, D. Crowley, M. Barry, R. T. Bronson, and R. O. Hynes Tumor-Secreted Vascular Endothelial Growth Factor-C Is Necessary for Prostate Cancer Lymphangiogenesis, but Lymphangiogenesis Is Unnecessary for Lymph Node Metastasis Cancer Res., November 1, 2005; 65(21): 9789 - 9798. [Abstract] [Full Text] [PDF]